Join the Class Action Suit Against Applied Therapeutics for Losses: What Investors Need to Know

Class Action Lawsuit Against Applied Therapeutics: Important Information for Investors

As a shareholder of Applied Therapeutics, Inc. (NASDAQ: APLT), if you've experienced a financial loss due to your investment, a class action lawsuit might provide the recovery you seek. The Gross Law Firm has issued a call to all affected investors to explore their legal options in response to significant declines in the company's stock price.

Background of the Case

Between January 3, 2024, and December 2, 2024, shareholders witnessed a steep decline of over 80% in the value of APLT shares. The decline began with a troubling press release from Applied Therapeutics on November 27, 2024, which disclosed that the company had received a Complete Response Letter (CRL) from the FDA. This letter indicated that the FDA was unable to approve the New Drug Application (NDA) for govorestat, the company’s lead drug candidate, due to deficiencies found in the clinical application.

The market responded negatively, and the share price fell from $10.21 per share on November 26 to $8.57 the following day. As the situation unfolded, the stock price continued to plummet to just $1.75 by December 2, 2024. The circumstances worsened when the company revealed that it had also received a